Pricing Log in Create free account

Acumen Pharmaceuticals, Inc. (ABOS) vs ALX Oncology Holdings Inc. (ALXO)

Acumen Pharmaceuticals, Inc. and ALX Oncology Holdings Inc. are both Biotechnology companies. ALX Oncology Holdings Inc. is the larger, with a market value of $138.3M against $120.8M — 1.1× the size. Across the 12 metrics below, ALX Oncology Holdings Inc. leads on 10 and Acumen Pharmaceuticals, Inc. on 2.

Valuation

Metric ABOS ALXO Biotechnology median
P/E n/m n/m 8.42
P/S 84.02 55.64 10.01
P/B 2.11 1.00 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m n/m 0.61
EV/Sales 29.27 5.06 9.41
Earnings yield (97.60%) (113.00%) (31.85%)
Free cash flow yield (76.15%) (52.28%) (24.58%)

Profitability

Metric ABOS ALXO Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (120.50%) (80.65%) (56.36%)
Return on assets (72.97%) (63.16%) (48.04%)
Return on invested capital 0.00% (673.30%) 0.00%

Growth

Metric ABOS ALXO Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (16.96%) 26.36% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABOS ALXO Biotechnology median
Debt to equity 0.55 0.07 0.00
Current ratio 2.47 9.71 4.72
Net debt to EBITDA 0.69 0.34 0.96

Dividend

Metric ABOS ALXO Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric ABOS ALXO Biotechnology median
Market cap 120.77m 138.28m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack